Company delivered double earnings beat with 24% revenue growth and significantly reduced net losses in Q4 2025. Strong performance of flagship RNS System product and favorable Medicare reimbursement decisions support positive outlook. However, sentiment is moderately positive rather than strongly positive due to muted 2026 guidance showing slower growth and increased losses, which limited investor enthusiasm.
Also mentions NPCE
Articles that tag NPCE but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
